Instil Bio公司2024年第四季度GAAP每股收益$(1.82)优于预期$(3.22),公司拥有现金、现金等价物、受限现金和有价证券共$1.151亿,预计可支撑现有运营计划到2026年之后

财报速递
04 Mar
Instil Bio(NASDAQ:TIL)报告季度每股亏损$(1.82),优于分析师一致预期的$(3.22),提高了43.48%。相比于去年同期的每股亏损$(1.99),增加了8.54%。

以上内容来自Benzinga Earnings专栏,原文如下:

Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(3.22) by 43.48 percent. This is a 8.54 percent increase over losses of $(1.99) per share from the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10